Dimitrios T.
- Country
- Greece
- Department
- 2nd Medical Oncology Department
Research Overview
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- Phase III Randomized Double-Blind Study of Alpelisib and Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer with PIK3CA Mutation
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 264 of 535 partner sites.
Specializations
Breast Cancer and Endocrine-Driven Disease
The investigator is active in clinical research for hormone receptor-positive, HER2-negative and HER2-positive breast cancer, with attention to early breast cancer, advanced breast cancer, metastatic breast cancer, and triple-negative breast cancer.
- ER+/HER2- early and advanced breast cancer
- PIK3CA-mutant and ESR1-mutated breast cancer
- Triple-negative breast cancer
- HER2-positive breast cancer
Research interests also include endocrine therapy strategies, CDK4/6 inhibitor-based treatment, and targeted approaches for recurrence prevention and disease control.
Lung Cancer and Thoracic Oncology
His trial portfolio includes multiple studies in non-small cell lung cancer and small cell lung cancer, spanning both advanced and limited-stage disease.
- PD-L1-high NSCLC
- KRAS G12C-mutant NSCLC
- RET fusion-positive NSCLC
- Relapsed and extensive-stage SCLC
Additional activity covers uncommon EGFR mutations and treatment settings that integrate immunotherapy, targeted therapy, and chemotherapy in thoracic malignancies.
Gastrointestinal and Genitourinary Cancers
The investigator is involved in studies of gastric cancer, gastroesophageal junction cancer, colorectal cancer, urothelial carcinoma, and prostate cancer.
- FGFR2b-overexpressing gastric and gastroesophageal junction cancer
- KRAS G12C-mutant metastatic colorectal cancer
- Locally advanced or metastatic urothelial carcinoma
- Metastatic castration-resistant and hormone-sensitive prostate cancer
His research also extends to biomarker-defined disease groups and treatment-resistant settings in solid tumors.
Hematologic Malignancies and Treatment Support
Clinical work includes multiple myeloma and supportive care research relevant to patients receiving systemic anticancer therapy.
- Relapsed multiple myeloma
- Minimal residual disease assessment
- Chemotherapy-induced thrombocytopenia
This area also includes strategies aimed at preserving treatment delivery during chemotherapy and monitoring disease response in plasma cell disorders.
Other Oncology and Inflammatory Disorders
His research landscape further includes head and neck squamous cell carcinoma, primary biliary cholangitis, and selected studies in pain management linked to cancer care.
- Locally advanced unresected head and neck cancer
- Primary biliary cholangitis
- Low back pain
These interests reflect involvement in both oncologic and non-oncologic therapeutic domains within internal medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.